share_log

Goldman Sachs Maintains Buy on Royalty Pharma, Raises Price Target to $51

Benzinga ·  Aug 14 19:10  · Ratings

Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $51.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment